GlassScriptPhysician profile
Cristian Constantinescu
NPI 1922778406
$10,163.96
in general payments reported to CMS, 2019-2025
22 companies · $4,149 in 2025
The $4,149 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,588 · 2023: $755 · 2024: $1,672 · 2025: $4,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,360 · Food and Beverage: $3,114 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,360.00 |
| Food and Beverage | $3,114.33 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $7,079.29 | 2022-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $564.01 | 2022-2025 | Vumerity, Tysabri, Leqembi |
| Abbvie INC. | $471.09 | 2024-2025 | |
| Horizon Therapeutics Plc | $447.68 | 2022-2023 | Uplizna, Tepezza |
| Amgen INC. | $226.34 | 2024-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $168.29 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Argenx US, INC. | $163.40 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $161.07 | 2024-2025 | Rystiggo, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $146.99 | 2023-2025 | Ultomiris |
| Pfizer INC. | $142.63 | 2025 | |
| Janssen Pharmaceuticals, INC | $140.08 | 2022 | |
| Celgene Corporation | $116.91 | 2022-2025 | Zeposia |
| Vanda Pharmaceuticals INC. | $80.61 | 2024-2025 | Ponvory |
| Neurocrine Biosciences, INC. | $39.51 | 2025 | |
| Lundbeck LLC | $36.35 | 2025 | Vyepti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $36.28 | 2025 | |
| Sk Life Science, INC. | $35.15 | 2025 | |
| Eisai INC. | $32.69 | 2025 | |
| Csl Behring | $20.00 | 2024 | Hizentra |
| Lilly USA, LLC | $19.54 | 2025 | Amyvid, Kisunla |
| Acadia Pharmaceuticals INC | $18.34 | 2025 | Nuplazid |
| Impel Pharmaceuticals LLC | $17.71 | 2025 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristian Constantinescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.